Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration - Takeaways - MDSpire

Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration

  • By

  • Hongyang Zhang

  • Rui Yang

  • Yu Ma

  • Jiahui Yang

  • Binyan Yang

  • Lingdi Dong

  • Nan Yu

  • April 24, 2026

  • 0 min

Share

  • 1

    Psoriasis is a chronic inflammatory skin disease driven by the IL-23/IL-17 axis, leading to significant systemic inflammation.

  • 2

    The study analyzed plasma samples from 10 psoriasis patients and 10 healthy controls using Olink proteomics to identify inflammatory biomarkers.

  • 3

    Key proteins like CXCL1, CXCL5, CCL20, and HGF showed significant differences between psoriasis patients and healthy individuals.

  • 4

    Secukinumab treatment resulted in a reduction of inflammatory mediators, with IL-17C levels correlating with disease severity.

  • 5

    This research provides insights into the systemic effects of IL-17A blockade and highlights potential biomarkers for monitoring psoriasis treatment.

Original Source(s)

Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration

  • by Hongyang Zhang, Rui Yang, Yu Ma, Jiahui Yang, Binyan Yang, Lingdi Dong, Nan Yu

  • April 24, 2026

Related Content

Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice

Coordinated Care Strategies for Psoriasis: An Organized Method for Timely Identification and Referral of Comorbid Conditions

Correction: Association between Life's Essential 8 and psoriasis in US adults: a cross-sectional study